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ABSTRACT 
Purpose: We evaluated the long-term safety and efficacy of an adjustable continence device (ACT® 
or ProACT®) in male and female patients with neurogenic SUI (nSUI). 
 
Materials and Methods: Data on patients consecutively treated with implantation of an adjustable 
continence device due to nSUI were reviewed from the start of our experience to the current 4-year 
follow-up. 
 
Results: We reviewed data on 13 male and 24 female patients with nSUI due to different forms of 
pelvic nerve or spinal cord lesions. Mean ± SD age at implantation was 46.2 ± 17.4 years. Of the 
patients 92% performed ISC. The device was implanted bilaterally using general and local anesthesia 
in 16.2% and 83.8% of cases, respectively. From before implantation to 48-month follow-up the mean 
number of urinary incontinence episodes decreased from 6.1 ± 2.4 to 2.8 ± 3.1 and the mean number 
of pads used per 24 hours decreased from 4.2 ± 2.7 to 2.2 ± 2.2. Of the patients 54.5% indicated more 
than 50% improvement of SUI symptoms after 48 months, of whom 38.9% indicated complete 
continence. Adverse events included erosion / migration, device infection or failure, implantation site 
pain, bladder stone formation and difficult ISC. 
 
Conclusions: Implantation of the ACT® / ProACT® device in patients with nSUI is minimally invasive 
and safe. It can significantly improve nSUI in the long term. Thus, it might be a reasonable option for 
patients who are not willing, not suitable or not yet ready for more invasive surgery, such as AUS or 
fascial suspension sling placement. 
 
Key words: urethra; prostheses and implants; stress urinary incontinence; spinal cord; treatment 
outcome 
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INTRODUCTION 
Neurogenic lesions, e.g. SCI or peripheral lesions of nerve fibers innervating the LUT, can cause nSUI 
due to sphincter and / or bladder neck insufficiency. Managing neurogenic sphincter deficiency 
remains a therapeutic challenge since to our knowledge there is no available medical treatment. 
Moreover, most patients must perform ISC to empty the bladder and are at higher risk for 
complications of any prosthetic implant used for continence [1]. 
The current, most frequently used surgical options for nSUI are an AUS [2, 3] or an obstructing fascial 
sling [4-6]. However, these procedures require open abdominal and pelvic surgery using general 
anesthesia and do not provide the opportunity for postoperative adjustment. Some patients do not 
desire or feel uncomfortable with an AUS or they do not have the dexterity to use such an implant. 
Others might not be good candidates for more invasive surgery or they might need additional 
continence support after previous surgery, i.e. fascial sling placement. Moreover, in patients with nSUI 
it would be desirable to have an adjustable continence device that allows for adaptation in regard to 
changes in continence function without undergoing further surgery or changing the implant. 
The ACT® / ProACT® device offers such adjustable continence support for male [7-10] and female 
[11] patients. The device consists of 2 balloons that are implanted in minimally invasive fashion on 
each side of the urethra. Small subcutaneous titanium ports allow refilling or deflation at any time. 
Good mid-term results with a 52% to 80% continence rate were achieved in non-neurogenic SUI 
populations with sphincter deficiency [7, 9-12]. However, long-term results of more than 2 years have 
been reported only for single cases. 
There is no available information on using ACT® / ProACT® for nSUI. Thus, to our knowledge we 
retrospectively investigated for the first time the safety and efficacy of the ACT® / ProACT® device in 
male and female patients with nSUI.  
 
PATIENTS AND METHODS 
Data on patients who were consecutively treated at our clinic (Department of Urology, Pitié-Salpêtrière 
Hospital, Assistance Publique-Hôpitaux de Paris, University Paris VI) with implantation of the ACT® or 
ProACT® adjustable continence device due to nSUI were reviewed from the start of our experience up 
to the current 4-year follow-up to determine long-term results. The frequency of ISC, urinary 
incontinence episodes (UIEs) and pad use was evaluated from follow-up data and compared to 
preoperative values. In addition, balloon volume, operative and postoperative adverse events, and 
patient reported treatment outcomes were evaluated from follow-up data. 
Statistical analysis was performed as applicable between pre-implantation and follow-up data using 
the Wilcoxon signed rank test with SPSS® 17.0. 
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RESULTS 
A total of 13 male and 24 female patients with nSUI were treated with ACT® / ProACT® at our clinic. 
Mean ± SD age at implantation was 46.2 ± 17.4 years. Of the 37 patients 19 had paraplegia at Th3 or 
below, 7 had spina bifida, 4 had cauda equina syndrome and 1 each had poliomyelitis, syringomyelitis, 
lumbar stenosis, multiple sclerosis, tetraplegia, pelvic polytrauma and peripheral nerve lesion following 
major pelvic surgery, each with subsequent nSUI (Table 1). 
A total of 14 patients received 1 or more previous urological treatments for nSUI, 21 underwent or 
were currently being treated for concomitant NDO and 5 received previous urological treatment for 
reasons other than nSUI or NDO (Table 1). Before implantation, the micturition mode was ISC and 
voluntary micturition in 34 and 3 patients, respectively. Additionally, 6 male patients used a condom 
catheter between ISC. 
Urodynamic data before implantation revealed a mean maximum cystometric capacity of 424 ± 147 
ml, a mean maximum detrusor storage pressure of 20.2 ± 11.3 cmH2O and a mean bladder 
compliance of 37.7 ± 21.8 ml/cmH2O. Mean urethral closure pressure was 22.6 ± 13.2 cmH2O. DO or 
poor bladder compliance was not detected on pre-implantation cystometry, which was a prerequisite 
for the procedure. SUI was noted in each patient during pelvic examination. 
All implantations were performed bilaterally under cystoscopic and fluoroscopic control by the same 
surgeon (ECK). All patients received prophylactic antibiotics at surgery. The detailed implantation 
technique was described previously [9-11]. The mean volume injected during implantation was 2.0 ± 
0.3 and 1.9 ± 0.4 ml for the right and the left balloon, respectively. Mean operative time was 25 ± 2.4 
minutes. 
In 6 patients the procedure was performed under general anesthesia. All other patients tolerated 
implantation well under local anesthesia. Mean hospital stay was 1.5 days (range 1 to 2). However, 
this reflects an administrative rather than a medical reason. 
During surgery or the postoperative hospital stay, a labial / scrotal hematoma developed in 2 patients, 
which was surgically removed in 1. In 3 patients small intraoperative urethral perforations resulted in 
immediate balloon repositioning on the side of the perforation and Foley catheter placement for 24 
hours. 
Follow-up was performed at 3, 6, 12, 24 and 48 months. Due to incomplete and missing data, 1 
patient data set was excluded from further analysis. Thus, the data sets of 36 patients were used for 
follow-up analysis. By 48 months another patient was lost to follow-up and 1 each had died of 
esophageal cancer and cardiac arrest. Thus, at 48-month follow-up 33 patient data sets were 
available. 
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Table 1 Patient characteristics, previous and current urological treatments 
Pt No. – 
Gender – 
Age [years] at 
implantation 
Neurologic lesion 
(cause) 
ASIA 
impairment 
scale/level 
of lesion 
Previous urological treatments 
Current urological 
treatments 
1 – F – 72 Poliomyelitis  none none 
2 – F – 41 
Paraplegia 
(infection) 
A/Th9 
Ileum bladder augmentation, suburethral sling 
from muscel fascia 
oral oxybutynin 
3 – F – 33 
Paraplegia 
(vascular) 
-/L5 none oral oxybutynin 
4 – F – 36 Paraplegia (trauma) A/Th10 
Botulinum toxin intradetrusor injections, Ileum 
bladder augmentation, trans vaginal tape 
none 
5 – M – 25 Syringomyelitis  none oral oxybutynin 
6 – M – 42 Spina bifida  Ileum bladder augmentation none 
7 – F – 49 Spina Bifida  Vesico-ureteral-reflux repair none 
8 – M – 69 
Cauda-Equina-
Syndrome (t) 
 Urethral stent, sacral neuromodulation oral oxybutynin 
9 – F – 55 Paraplegia (trauma) A/Th12 trans vaginal tape none 
10 – F – 72 
Cauda-Equina-
Syndrome 
(Ca surgery) 
 sacral neuromodulation none 
11 – F – 37 
Peripheral nerve 
lesion following 
major pelvic surgery 
 sacral neuromodulation none 
12 – M – 30 Spina bifida  Ileum bladder augmentation none 
13 – F – 68 Lumbar stenosis  Ileum bladder augmentation, trans vaginal tape oral oxybutynin 
14 – F – 46 Multiple sclerosis  
Ileum bladder augmentation + continent urinary 
diversion, suburethral sling from muscle fascia 
oral oxybutynin 
15 - F – 32 Spina bifida  none none 
16 – F – 30 Paraplegia (trauma) A/Th12 none oral oxybutynin 
17 – F – 26 Pelvic polytrauma  
AMS800 (’88 – ’05), Ileum bladder 
augmentation, vesico-ureteral-reflux repair 
none 
18 – M – 62 
Paraplegia 
(Ca surgery) 
A/L1 Radical prostaectomy oral oybutynin 
19 – M – 55 
Cauda-Equina-
Syndrome 
 Orchiectomy none 
20 – M – 53 Paraplegia (trauma) A/Th11 Ileum bladder augmentation, sphincterotomy oral oxybutynin 
21 – F – 58 Paraplegia -/Th12 Promontofixation, bladder neck closure oral oxybutynin 
22 – F – 14 Spina bifida  Sigmoid cystoplasty, bladder neck reconstruction none 
23 – F – 46 Paraplegia (trauma) A/Th11 
Trans vaginal tape, hysterectomy, 
promontofixation, Ileum bladder augmentation + 
Mitrofanoff catherizable stoma 
oral oxybutynin, 
intradetrusor injections 
with botulinum toxin 
24 – F – 56 Paraplegia A/Th12 
Ileum bladder augmentation + Mitrofanoff 
catherizable stoma, trans vaginal tape 
oral oxybutynin 
25 – F – 64 
Paraplagia 
(Ca surgery) 
C/Th3 none none 
26 – F – 27 Paraplegia (trauma) A/L1 suburethral sling from muscle fascia none 
27 – F – 83 Spina bifida  none none 
8 – F – 76 
Cauda-Equina-
Syndrome 
(Ca surgery) 
 none none 
29 – M – 36 Paraplegia (trauma) D/Th12 none none 
30 – M – 30 Paraplegia (trauma) A/Th12 
vesico-ureteral-reflux repair, bladder stone 
extraction 
none 
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Pt No. – 
Gender – 
Age [years] at 
implantation 
Neurologic lesion 
(cause) 
ASIA 
impairment 
scale/level 
of lesion 
Previous urological treatments 
Current urological 
treatments 
31 – M – 71 Paraplegia (trauma) A/Th10 none none 
32 – M – 36 Paraplegia (trauma) A/Th10 none none 
33 – M – 44 Paraplegia (trauma) A/L5 none oral oxybutynin 
34 – F – 41 Paraplegia (trauma) A/L4 Promontofixation, trans vaginal tape none 
35 – F – 23 Spina bifida  Pippi-Salle procedure, trans vaginal tape none 
36 – M – 35 Tetraplegia  Urethral stent, urethrotomy oral oxybutynin 
37 – F – 35 Paraplegia (trauma) B/L3 Promontofixation, trans vaginal tape oral oxybutynin 
F = female, M = male, ASIA = American Spinal Injury Association, L = lumbar, Th = thoracic 
 
Table 2 lists balloon volume, the frequency of ISC, UIEs and pad use, and patient reported treatment 
outcomes. The micturition mode did not change in any patient postoperatively. 
A total of 74 adverse events involved the 2 balloons or the balloon on only one side. Therefore, 
adverse events are not presented per patient but rather per balloon (Table 3). Overall, we noted 
device erosion/migration for 15 of the 74 balloons (20.3%), device infection for 5 (6.8%), implantation 
site pain for 5 (6.8%), and device failure (i.e. balloon leakage), bladder stone formation and difficult 
ISC for 2 each (2.7%). Balloons eroded / migrated more frequently into the urethra than into the 
bladder (13 vs 2 of 15). Adverse events were generally mild and only temporary due to easy, timely 
balloon explantation as an outpatient procedure without anesthesia. In cases of infection additional 
treatment with oral antibiotics was sufficient. 
The number of patients who required or asked for device explantation was 5 of 36 (13.8%) at 3 
months, 4 of 36 (11.1%) at 6 months, 2 of 36 (5.5%) at 12 months, 4 of 36 (11.1%) at 24 months and 9 
of 33 (27.3%) at 48 months (Table 3). In 11 patients devices were only temporarily explanted and 
could be successfully re-implanted after 3 to 24 weeks (Table 3). Thus, the device was permanently 
explanted by the end of the 48-month follow-up in 13 of 33 patients (39.4%). Reasons for permanent 
removal were adverse events and the inefficacy of nSUI treatment. 
Of the patients with permanently removed devices 4 underwent AUS implantation, 3 were treated with 
bladder neck closure combined with continent cutaneous urinary diversion and 2 received an ileal 
conduit. 
 
DISCUSSION 
The implantation of adjustable paraurethral balloons significantly decreased the number of UIEs and 
pad use in patients with nSUI. However, only 21% of patients attained complete continence and 
39.4% required permanent explantation of the device after 4 years of follow-up. Nevertheless, greater 
than 50% improvement was reported by 67.6% and 64.8% of patients, including those who achieved 
complete continence, at 1 and 2 years of follow-up, respectively. 
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Table 2 Results on ballon volume, frequency of intermittend self-catheterization (ISC), urinary incontinence episodes (UIE), pad 
use, and patient reported outcome at baseline and follow-up after 3, 6, 12, 24, and 48 months. 
 Baseline 
Follow-up (months) 
3 6 12 24 48 
Mean ± SD balloon vol 
(ml): 
      
right  2.8 ±1.1 3.6 ±1.6 3.7 ±1.8 3.9 ±2.1 4.1 ±2.2 
left  3.0 ±0.8 3.6 ±1.5 3.9 ±1.7 4.2 ±2.0 4.3 ±2.0 
Mean ± SD No./24 hrs:       
ISCs 5.4 ±1.7 5.1 ±1.6, 5.0 ±1.7 5.2 ±1.7 5.2 ±1.9 5.6 ±1.7 
UIE 6.1 ±2.4 3.9 ±3.2 4.1 ±2.9 3.1 ±3.4 3.2 ±3.4 2.8 ±3.1 
p Value*  0.001 0.002 < 0.001 < 0.001 0.001 
Pad use 4.2 ±2.7 2.3 ±2.2 2.4 ±2.3 1.8 ±2.0 2.4 ±2.5 2.2 ±2.2 
p Value*  0.001 0.004 0.001 < 0.001 0.004 
No. pt reported (%):  36 36 36 36 33 
complete continence  6 (16.7) 6 (16.7) 7 (19.4) 5 (13.8) 7 (21.2) 
50% or greater 
improvement 
 14 (39.0) 17 (47.2) 18 (50.0) 19 (52.8) 11 (33.3) 
treatment failure or less 
than 50% improvement 
 16 (44.4) 11 (30.5) 8 (22.2) 7 (19.4) 2 (6) 
permanent device 
explantation 
 0 2 (5.6) 3 (8.3) 5 (13.9) 13 (39.4) 
* = significant different vs baseline 
 
Previous groups that investigated the efficacy of the adjustable continence device in female and post-
prostatectomy SUI cases reported a success rate of 52% to 80% (proportion of completely continent 
patients) [7, 9-12]. However, in the latter studies non-neurogenic patients had at least some sphincter 
and pelvic floor function remaining. In our patient population sphincteric and pelvic floor function was 
absent, explaining the discrepancy in efficacy rates between the current and previous studies. The 
type of neurological lesion might have influenced the results but this could not be statistically 
demonstrated in our study due to our small, mixed study population. However, according to daily 
clinical experience the degree of disability / mobility seems to be more important for the therapeutic 
outcome than the type of neurological lesion because there is high variability in nSUI severity even for 
the same type of neurological lesion. 
Usually, postoperative adjustment is necessary to optimize the effect on urinary continence. Best 
outcomes were reported after 4 or 5 refillings [9]. In our patients refilling was done more rapidly during 
the first 6 months to achieve continence more quickly. Further refilling was needed less frequently and 
performed more cautiously to prevent trouble with ISC. 
The most common intraoperative and postoperative complications using the adjustable continence 
device reported in the current literature are erosion in 2.5% to 7.5% of cases, urinary retention in 1.2% 
to 6.3%, migration in 3.8% to 5.6%, perforation in 2.5% to 18%, therapy failure in 2.5%, and urinary 
tract infections in 1.9% to 5% [7-12]. Other complications, such as wound infection in 0.6% to 8% of 
cases, implantation site pain in 0.6% to 15%, de novo urgency in 5% and device / material failure in 
0.6% to 4% were less common [11] except in the study by Gilling et al. [7]. In most cases 
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complications were described as mild and quickly correctable. The reported explantation rate is 
between 8% and 58% [7-11]. Within 12 months after explantation successful reimplantation could be 
performed in most cases [11, 12]. 
Complication and explantation rates in our study of the ACT® / ProACT® device in an nSUI population 
are well within the ranges reported in the current literature. However, urinary retention is less relevant 
in our nSUI population of patients, who perform ISC. The fact that 92% of our patients performed ISC 
and 37.8% of them had undergone previous SUI surgery seems not to have negatively affected our 
complication rate. 
 
Table 3 Adverse events in 74 ballon cases during follow-up 
Follow-up 
(months) 
No. Ballons* No. Pts / No. Ballons 
Errosion / 
Migration 
(site) 
Infection 
(type) 
Pain 
Device 
failure 
Other 
(cause) 
Removal 
Re-
implantation 
3 
4 
(urethra) 
2 
(device) 
 
1 
(balloon leak) 
 5 / 7 3 / 3 
6 
6 
(5x urethra, 
1x bladder) 
    4 / 7 3 / 5 
12 
1 
(bladder) 
1 
(orchido-
epidydimitis) 
2  
3 
(2x bladder 
stone, 
1x difficult ISC) 
2 / 4 1 / 2 
24 
2 
(urethra) 
1 
(device) 
2 
1 
(balloon leak) 
1 
(difficult ISC) 
4 / 7 3 / 5 
48 
2 
(urethra) 
1 
(device) 
1   9 / 17 1 / 1 
Totals 15 5 5 2 4 24 / 42 11 / 16 
*No patient had urethral stricture. ISC intermittend self-catheterisation 
 
Concomitant NDO that is not treated or insufficiently treated can adversely influence the complication 
rate and study outcome in our patient population. Thus, in neurogenic cases it is important to strictly 
determine whether urinary incontinence is related to NDO or whether it is true SUI due to sphincter 
and / or bladder neck insufficiency [13]. This distinction can only be made by urodynamic 
investigations using filling cystometry, as in our study. All of our patients had cystometric parameters 
within the normal range and no DO. Those known to have NDO were under adequate treatment. 
Other surgical therapies for SUI include bulking agents, suburethral or bladder neck slings / tapes and 
AUS implants. Bulking agents comprise different products of different materials, eg collagen, 
autologous fat, silicon, carbon, polytetrafluoroethylene and polyacrylamide hydrogel. Due to initially 
rather low therapeutic success and sparse data [14], this therapy form is not well established. There 
are hardly any investigations of the application of bulking agents for nSUI. Two studies in children with 
nSUI showed rather unsatisfactory results [15, 16]. Almost all bulking agents migrate, or cause erosion 
or granulomas [14, 17]. Re-injections are frequently required for adequate efficacy [14]. 
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Autologous suspension slings, i.e. rectus fascia, are often used for female and male nSUI with a 
complete continence rate of 66.6% to 69.2% (mean 68.3%) in the adult population [4-6] and 14% to 
95% (mean 68.4%) in the pediatric population [18-20]. However, most sling procedures are performed 
in combination with augmentation cystoplasty, which potentially contributes to the beneficial outcome 
of nSUI [19]. 
Although most patients with nSUI performed ISC, studies of autologous fascia slings in adult and 
pediatric patients with nSUI show only a few, less severe adverse events than those reported for tape 
and sling implantation in the more general SUI population [21, 22]. Two available studies show 
midterm and long-term outcomes of tension-free vaginal tape implantation in an adult female nSUI 
population with continence in 83.3% at 2 years [23] and in 77% at 10 years [13]. 
The AUS is used in men and less frequently in women [24, 25]. Due to its high efficacy in terms of the 
continence rate of 58% to 88% (proportion of completely continent patients), today it is the gold 
standard treatment for male SUI [26]. Patients with nSUI, in whom an AUS is an established treatment 
option, have also largely benefited from this therapy [24]. The success rate (proportion of completely 
continent patients) for nSUI is reportedly between 23% and 91% (mean 73%) [2, 27-30]. 
However, the AUS is expensive and requires a somewhat complex surgical procedure that may be 
associated with significant complication and revision rates [12]. Common complications are erosion, 
infection and mechanical / product related failure, causing an overall 16% to 80% revision and 
explantation rate [2, 28-30]. Murphy et al compared treatment outcomes between patients with nSUI 
and those with non-neurogenic SUI [27]. According to those results, patients with nSUI seem to have 
non-mechanical / non-product related complications more frequently, which was attributable to a 
higher rate of previous LUT surgeries in patients with nSUI. ISC and wheelchair dependency 
potentially also contribute to the higher complication rate in neurogenic cases. 
Despite the rather average effectiveness in our study, special circumstances in patients with nSUI 
must be considered, such as complete sphincter insufficiency and a yawning bladder neck, i.e. in 
those with spina bifida. However, the adjustable balloons offer certain advantages. 1) Application is 
safe with few intraoperative and immediate postoperative complications even in neurogenic cases with 
previous LUT surgery. 2) The short, minimally invasive procedure allows for fast healing and a short 
hospital stay or even ambulatory treatment. 3) There is quick, uncomplicated ambulatory adaptation of 
balloon volumes according to patient needs [9]. 4) In contrast to slings / tapes or bulking agents, 
balloons can be explanted as ambulatory surgery using local anesthesia in case of adverse events 
with the option of re-implantation at 3 months. 5) Balloon implantation or explantation does not limit 
the implantation of other continence devices, i.e. an AUS, at a later time. 
Although to our knowledge this is the first study evaluating the efficacy and safety of the ACT® / 
ProACT® system in an nSUI population, certain limitations must be considered. 1) Our study was not 
a randomized, prospective study. Nevertheless, our data are representative of everyday clinical 
practice. 2) Patient reported outcomes were not obtained anonymously from questionnaires but from 
chart reviews. 3) QoL before and after implantation was not systematically assessed and, therefore, 
could not be evaluated.  
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CONCLUSIONS 
ACT® / ProACT® implantation in patients with nSUI can be performed as a short, minimally invasive 
procedure. The safety profile is good with intraoperative and postoperative complications that are self-
limited or easily manageable, even in neurogenic patients who mainly performed ISC and / or 
underwent previous SUI surgery. Efficacy seems to be somewhat limited, probably due to the severity 
of the continence deficiency in neurogenic patients. Nevertheless, UIEs and pad use were significantly 
decreased throughout the 4-year follow-up. The ACT® / ProACT® system appears to be an interesting 
alternative for nSUI, especially for patients who need additional continence support after previous 
nSUI surgery or those who are not willing, not suitable or not yet ready for more invasive surgery. 
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